Study Details

Back
Study ID 178-CL-101
Study Title A randomized, double-blind, parallel-group, placebo- and active- controlled, multicenter study to evaluate the efficacy, safety and tolerability of combinations of Solifenacin Succinate and Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in the treatment of overactive bladder
Clinicaltrials.gov Identifier NCT01972841
Compound Name EB178 / mirabegron + solifenacin succinate
Medical Indication or Disease Overactive bladder
Study Sponsor Astellas Pharma Europe B.V.
Collaborator Not Applicable
Study Start Date 05-Nov-2013
Study Completion Date 22-Oct-2015
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS